Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, today announced that it will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results